0001104659-21-060967.txt : 20210504 0001104659-21-060967.hdr.sgml : 20210504 20210504160705 ACCESSION NUMBER: 0001104659-21-060967 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210504 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210504 DATE AS OF CHANGE: 20210504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980505495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37852 FILM NUMBER: 21888442 BUSINESS ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 BUSINESS PHONE: (510) 474-0170 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 8-K 1 tm2115076d2_8k.htm FORM 8-K
0001377121 false 0001377121 2021-05-04 2021-05-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 4, 2021

 

 

 

PROTAGONIST THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37852   98-0505495
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

Protagonist Therapeutics, Inc.

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

 

(510) 474-0170

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.00001   PTGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 4, 2021, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2021. A copy of the press release titled “Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 9.01  Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press release, dated May 4, 2021, titled “Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update.”
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Protagonist Therapeutics, Inc.
   
Dated: May 4, 2021  
  By: /s/ Don Kalkofen 
  Don Kalkofen
    Chief Financial Officer

 

 

 

 

 EX-99.1 2 tm2115076d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Protagonist Reports First Quarter 2021

Financial Results and Provides Corporate Update

 

NEWARK, California, May 4, 2021 – Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or “the Company”) today reported financial results for the first quarter of 2021 ended March 31, 2021 and provided a corporate update.

 

“Our progress this quarter affirms the strength of our pipeline and execution capabilities,” said Dinesh Patel, PhD, Protagonist’s President and Chief Executive Officer. “For our lead drug candidate, rusfertide in polycythemia vera, we have completed enrollment for our Phase 2 study and confirmed the registrational path forward based on recent engagement with both U.S. and European regulators. We look forward to providing an interim update from our ongoing Phase 2 study at a major medical conference in the second quarter of 2021.”

 

Dr. Patel continued, “We are very pleased with the rate of enrollment in our ongoing Phase 2 study of the oral alpha-4-beta-7-integrin antagonist PN-943. For our oral IL-23 receptor antagonists, we expect to dose the first subject in the Phase 1 study of PN-232 in the second quarter of 2021 and intend to complete both this trial and the Phase 1 trial of PN-235 during the second half of 2021. There is excellent movement forward across our full portfolio, driven by our commitment to patients in need of new and better therapeutic options.”

 

PRODUCT DEVELOPMENT AND CORPORATE UPDATE

 

Disorders of Red Blood Cells and Iron Regulation

 

Rusfertide (PTG-300)

 

Investigational, injectable, hepcidin mimetic discovered through our peptide technology platform. Hepcidin is a natural hormone that regulates iron homeostasis and controls the absorption, storage, and distribution of iron in the body. Rusfertide is currently being evaluated for disorders associated with iron overload and excessive erythrocytosis (red blood cell production).

 

·In March 2021, following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) and written comments from the European Medicines Agency (“EMA”), Protagonist has advanced its preparations for a global pivotal study of rusfertide in polycythemia vera (“PV”). The Company plans to initiate this Phase 3 study in early 2022.

 

·In April 2021, Protagonist announced completion of enrollment in the ongoing Phase 2 study of rusfertide in PV. The Company plans to present updated interim data from this study at an upcoming medical meeting in the second quarter of 2021.
   
 · In the second half of 2021, Protagonist expects to announce preliminary results from the ongoing Phase 2 open-label proof-of-concept study of rusfertide in patients with hereditary hemochromatosis ("HH").

 

·In addition to ongoing studies in PV and HH, the Company expects to select a third indication for rusfertide in 2021.

 

 

 

 

Inflammatory Bowel Diseases

 

PN-943

 

Investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel diseases.

 

·The 150-patient Phase 2 “IDEAL” study evaluating the safety, tolerability and efficacy of PN-943 in patients with moderate to severe ulcerative colitis is underway, and the study is on track for completion in 2022.

 

Oral IL-23 Receptor Antagonists

 

PTG-200; PN-235; PN-232 (Janssen collaboration)

 

Investigational, orally delivered, IL-23 receptor antagonists. Protagonist has entered into a worldwide agreement with Janssen to co-develop and commercialize these drug candidates.

 

·In the second quarter of 2021, Protagonist expects to dose the first subject in the Phase 1 study of PN-232. The Company expects to complete both this trial and the Phase 1 trial of PN-235 in the second half of 2021. PN-232 and PN-235 are part of the oral IL-23 pathway blocker portfolio strategy, pursued in collaboration with Janssen.
   
·Enrollment continues for the Phase 2a proof-of-concept PRISM study of PTG-200, a first-generation drug candidate for patients with moderate to severe Crohn's disease.

 

First Quarter 2021 Financial Results

 

·Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2021 were $279.7 million. The Company expects current cash, cash equivalents and marketable securities to be sufficient to fund its planned operating and capital expenditures through the first half of 2024.

 

·License and Collaboration Revenue: License and collaboration revenue was $6.2 million for the first quarter of 2021 compared to $3.6 million for the same period of 2020. The increase was primarily due to the additional services provided to Janssen under the collaboration agreement during 2021 related to PN-232 and PN-235.

 

·Research and Development (“R&D”) Expenses: R&D expenses for the first quarter 2021 were $24.2 million as compared to $18.8 million for the same period of 2020. The increase was primarily due to costs associated with advancing our clinical trials with our pipeline assets of rusfertide and PN-943, as well as our three IL-23 receptor antagonist assets under the Janssen collaboration (PTG-200, PN-235 and PN-232).

 

·General and Administrative (“G&A”) Expenses: G&A expenses for the first quarter 2021 were $6.0 million as compared to $4.6 million for the same periods of 2020. The increase was primarily related to professional fees and employee compensation related expenses supporting the growth in our operations.

 

·Net Loss: The first quarter net loss was $24.0 million, or a net loss of $0.54 per share, compared to the first quarter of 2020 net loss of $20.1 million, or a net loss of $0.72 per share.

 

 

 

 

About Protagonist Therapeutics

 

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development. Rusfertide (PTG-300) is an investigational, injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. Based on the feedback provided by the FDA and EU regulatory authorities, the Company plans to initiate a single, global, Phase 3 randomized, placebo-controlled trial evaluating the efficacy of a once weekly, subcutaneously self-administered dose of rusfertide.

 

PN-943 is an investigational orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates, PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms. Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.

 

Cautionary Note on Forward-Looking Statements

 

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, our plans to conduct a Phase 3 trial evaluating rusfertide for PV, the timing of initiation and completion of other clinical trials and the timing of clinical data announcements. In some cases, you can identify these statements by forward looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, the impact of the ongoing COVID-19 pandemic on our discovery and development efforts, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our Quarterly Report on Form 10-Q for the three months ended March 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

 

 

 

 

PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations

(Unaudited)
(Amounts in thousands except share and per share data)

 

   Three Months Ended 
   March 31, 
   2021   2020 
License and collaboration revenue - related party  $6,189   $3,647 
Operating expenses:          
Research and development (1)   24,245    18,768 
General and administrative (1)   5,965    4,576 
Total operating expenses   30,210    23,344 
Loss from operations   (24,021)   (19,697)
Interest income   102    526 
Interest expense   —    (243)
Other expense, net   (79)   (490)
Loss before income tax expense   (23,998)   (19,904)
Income tax expense   -    (176)
Net loss  $(23,998)  $(20,080)
Net loss per share, basic and diluted  $(0.54)  $(0.72)
Weighted-average shares used to compute net loss per share, basic and diluted   44,224,169    27,703,918 

 

(1) Amounts include non-cash stock-based compensation expense.

 

 

 

 

Stock-based Compensation

(In thousands)

 

   Three Months Ended 
   March 31, 
   2021   2020 
Research and development  $1,475   $1,066 
General and administrative   1,185    982 
Total stock-based compensation expense  $2,660   $2,048 

 

PROTAGONIST THERAPEUTICS, INC.
Selected Consolidated Balance Sheet Data
(In thousands)

 

   March 31,   December 31, 
   2021   2020 
Cash, cash equivalents and marketable securities  $279,730   $307,809 
Working Capital   250,993    275,365 
Total assets   298,072    324,468 
Deferred revenue-related party   5,768    14,477 
Accumulated deficit   (307,809)   (283,811)
Total stockholders' equity   259,334    279,606 

 

SOURCE Protagonist Therapeutics, Inc.

 

Investor Relations & Media: Jami Taylor, Protagonist Therapeutics, Tel: +1.510.474.0170 ext. 300, Email: j.taylor@ptgx-inc.com; Rebecca John, Solebury Trout, Tel: +1.646.378.2935, Email: rjohn@soleburytrout.com

 

 

 

 EX-101.SCH 3 ptgx-20210504.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ptgx-20210504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ptgx-20210504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2115076d2_ex99-1img001.jpg GRAPHIC begin 644 tm2115076d2_ex99-1img001.jpg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end XML 7 tm2115076d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001377121 2021-05-04 2021-05-04 iso4217:USD shares iso4217:USD shares 0001377121 false 8-K 2021-05-04 PROTAGONIST THERAPEUTICS, INC. DE 001-37852 98-0505495 Protagonist Therapeutics, Inc. 7707 Gateway Blvd. Suite 140 Newark CA 94560-1160 510 474-0170 false false false false Common Stock, par value $0.00001 PTGX NASDAQ true true XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
May 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 04, 2021
Entity File Number 001-37852
Entity Registrant Name PROTAGONIST THERAPEUTICS, INC.
Entity Central Index Key 0001377121
Entity Tax Identification Number 98-0505495
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Protagonist Therapeutics, Inc.
Entity Address, Address Line Two 7707 Gateway Blvd.
Entity Address, Address Line Three Suite 140
Entity Address, City or Town Newark
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94560-1160
City Area Code 510
Local Phone Number 474-0170
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001
Trading Symbol PTGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://protagonist-inc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2115076d2_8k.htm ptgx-20210504.xsd ptgx-20210504_lab.xml ptgx-20210504_pre.xml tm2115076d2_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2115076d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2115076d2_8k.htm" ] }, "labelLink": { "local": [ "ptgx-20210504_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ptgx-20210504_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ptgx-20210504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ptgx", "nsuri": "http://protagonist-inc.com/20210504", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115076d2_8k.htm", "contextRef": "From2021-05-04to2021-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://protagonist-inc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2115076d2_8k.htm", "contextRef": "From2021-05-04to2021-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://protagonist-inc.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-060967-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-060967-xbrl.zip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